← Library
Tesamorelin
FDA ApprovedSince 2010
Also known as Egrifta, Egrifta SV
Function
Primary
HIV-associated lipodystrophy · Visceral fat reduction
Secondary
Cognitive aging (investigational)
Mechanism
Stabilized GHRH analog — stimulates GH release, reduces visceral adiposity; Phase II data for cognitive decline in MCI/Alzheimer's.
Evidence
Clinical RCT (Phase III)
Research
Phase III Theratechnologies; Phase II cognition data
Dosing
Range
2 mg/day
Frequency
Once daily
Route
Subcutaneous
Administration & Technique
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
Device31G × 5/16" insulin syringe (U-100). 100 units = 1 mL.
TechniquePinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Injection & Application Sites
Front
Back
Subcutaneous (SubQ)
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous; periodic IGF-1 monitoring.
Timing & Interactions
When to take
Once daily, evening, subcutaneous (abdomen). Consistent timing improves visceral-fat outcomes.
Do not combine with
- ·CJC-1295 with DAC — redundant long-acting GHRH
- ·Active malignancy — contraindicated
Complements
- ·Ipamorelin for pulse amplification (short cycles)
Storage & Reconstitution
Powder (Pre-Reconstitution)
Lyophilized powder: refrigerate 2–8°C for up to 24 months, or freeze at –20°C for extended storage. Keep sealed, desiccated, and protected from light.
After Reconstitution
After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Discard if cloudy, discolored, or precipitated.
Notes
Do not freeze after reconstitution — freeze/thaw cycles degrade most peptides.
Reconstitution Calculator
Concentration
2.50 mg/mL
Volume per dose
0.100 mL
Insulin syringe
10.0 units (U-100)
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Your Notes
Sign in to save personal notes on Tesamorelin and sync them to Vial Lab.
Benefits
- ·Visceral fat reduction
- ·Improved lipid profile
- ·Possible cognitive benefits in MCI
Risks
- ·IGF-1 elevation (monitoring required)
- ·Fluid retention
- ·Arthralgia
- ·Hyperglycemia
Contraindications
- ·Active malignancy
- ·Hypopituitarism with GH deficiency only
- ·Pregnancy
Regulatory
FDA-Approved (HIV lipodystrophy); off-label longevity use
Veterinary Use (Pets)
No established veterinary protocol for Tesamorelin. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
- Falutz J et al. Effects of tesamorelin on visceral fat in HIV-associated lipodystrophy. N Engl J Med. 2007;357:2359.source